Form 4: Tourmaline Bio CEO Acquires 226,000 Employee Stock Options
SEC Form 4 Filing
Tourmaline Bio's CEO, Sandeep Chidambar Kulkarni, reports the acquisition of 226,000 employee stock options.
Summary
- Sandeep Chidambar Kulkarni, CEO of Tourmaline Bio, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 226,000 employee stock options on February 3, 2025.
- The exercise price of the options is $15.54.
- The options vest as to 25% on February 3, 2026, and the remainder vests in 36 equal monthly installments, contingent upon continued service.
- The options expire on February 2, 2035.
- Following the transaction, Kulkarni directly owns 226,000 derivative securities.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The grant of stock options is generally viewed as a positive incentive for management, but the impact is not significant enough to warrant a higher score.
Positives
- The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Stakeholder Impact
- Shareholders may view the granting of stock options to the CEO as a way to align management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction (grant date of stock options) |
| 02/03/2026 | 25% of the shares subject to the option vest |
| 02/02/2035 | Expiration date of the stock options |
| 02/04/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.